Ginkgo Bioworks (NYSE:DNA) Stock Price Up 9.3% – Time to Buy?

24 Jun 2026, 17:41 by Kim Johansen · The Markets Daily

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report)’s stock price rose 9.3% during mid-day trading on Wednesday . The company traded as high as $9.61 and last traded at $9.6880. Approximately 500,503 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 1,182,675 shares. The stock had previously closed at $8.86.

Analysts Set New Price Targets

DNA has been the topic of a number of research reports. BTIG Research reduced their target price on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a report on Thursday, March 12th. Wall Street Zen lowered Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Reduce” and an average target price of $8.50.

Check Out Our Latest Analysis on Ginkgo Bioworks

Ginkgo Bioworks Stock Up 6.5%

The business’s 50 day moving average is $8.39 and its 200 day moving average is $8.34. The company has a market cap of $616.59 million, a P/E ratio of -1.76 and a beta of 1.79.

Ginkgo Bioworks (NYSE:DNA – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.18). The firm had revenue of $19.00 million during the quarter, compared to the consensus estimate of $42.93 million. Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.

Insider Transactions at Ginkgo Bioworks

In related news, insider Jason R. Kelly sold 109,767 shares of the firm’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $6.40, for a total transaction of $702,508.80. Following the completion of the transaction, the insider owned 316,483 shares of the company’s stock, valued at $2,025,491.20. This trade represents a 25.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven P. Coen sold 33,171 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $6.41, for a total value of $212,626.11. Following the completion of the transaction, the insider directly owned 49,849 shares of the company’s stock, valued at approximately $319,532.09. This trade represents a 39.96% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 542,580 shares of company stock valued at $3,546,784 over the last three months. Company insiders own 12.69% of the company’s stock.

Hedge Funds Weigh In On Ginkgo Bioworks

Large investors have recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Ginkgo Bioworks by 3.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,727 shares of the company’s stock worth $267,000 after purchasing an additional 1,122 shares in the last quarter. Shay Capital LLC raised its position in shares of Ginkgo Bioworks by 6.2% in the second quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock valued at $218,000 after buying an additional 1,124 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Ginkgo Bioworks by 3.5% during the 4th quarter. Deutsche Bank AG now owns 35,689 shares of the company’s stock worth $297,000 after purchasing an additional 1,207 shares during the last quarter. Green Alpha Advisors LLC lifted its position in Ginkgo Bioworks by 10.6% during the fourth quarter. Green Alpha Advisors LLC now owns 14,327 shares of the company’s stock worth $119,000 after buying an additional 1,378 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Ginkgo Bioworks by 2.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 94,873 shares of the company’s stock worth $789,000 after acquiring an additional 1,869 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Company Profile

(Get Free Report)

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.